Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase
UMass Chan AffiliationsDepartment of Pathology
Department of Medicine, Division of Hematology Oncology
MetadataShow full item record
AbstractIn summary, we show rapid and deep remission induced by blinatumomab in CD19(+) blast phase CML. Clinicians may consider the use of bispecific T-cell engager therapy as a bridge to transplant. Additional studies are needed before expanding the US Food and Drug Administration indication of blinatumomab to include lymphoid blast phase CML.
Patel SA, Bledsoe JR, Higgins AW, Hutchinson L, Gerber JM. Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase. JCO Precis Oncol. 2021 Jul 9;5:PO.21.00039. doi: 10.1200/PO.21.00039. PMID: 34409243; PMCID: PMC8367045. Link to article on publisher's site